On Wednesday, 2 July, the European Commission launched its new Life Sciences Strategy to make Europe a global leader in life sciences by 2030.
The strategy includes the following three main action points:
- Optimising the research and innovation ecosystem: The Commission will develop an EU investment plan to facilitate funding for multi-country clinical trials and strengthen European clinical research infrastructures. A One Health approach to research and Innovation will be promoted, as well as €100 million in funds under the Horizon Europe work programmes. A further €250 million will be mobilised for cross-sectoral life sciences technologies.
- Enabling rapid market access for life science innovations: The Commission will propose an EU Biotech Act to create a more innovation-friendly framework across biotech sectors – launching a matchmaking interface to connect startups, industry and investors.
- Boosting trust, uptake and use of innovation: The Commission will mobilise €300 million to stimulate the procurement of life science innovation in areas such as climate adaptation, next-generation vaccines and affordable cancer solutions. There will also be a Life Sciences Coordination Group to align policies and funding across sectors.
Additionally, the Commission will be ready to propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics, with a view to facilitating businesses’ operations across the EU Single Market and effectively protecting patient safety and public health. The Commission will also create a network of European Centres of Excellence to increase R&I in Advanced Therapy Medicinal Products (ATMPs).
The European Commission’s new Life Science Strategy marks a significant step toward positioning the EU as a global leader in health innovation by 2030. The strategy reflects a commitment to enhancing the research ecosystem and simplifying regulatory pathways. By facilitating multi-country clinical trials, supporting ATMPs, and aligning cross-sectoral funding, the EU aims to overcome current fragmentation in life sciences development. Notably, the EU Biotech Act could improve private investment and industry collaboration. This strategy has the potential to strengthen Europe’s competitiveness, accelerate patient access to cutting-edge therapies, and align economic growth with public health priorities.
